CLINICAL TRIALS PROFILE FOR CARVEDILOL

All Clinical Trials for carvedilol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00060918 ↗	Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension	Completed	GlaxoSmithKline	Phase 4	2001-06-01	To evaluate the effects of two different antihypertensive medications in the drug class of beta-blockers on control of glucose in Type II diabetic patients with high blood pressure.
NCT00052026 ↗	Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure	Completed	University of Utah	Phase 3	2000-05-01	The purpose of this study is to determine whether a new medicine, called carvedilol, improves symptoms and heart function in children who have congestive heart failure (diminished function of their heart muscle that pumps blood to the body). To accomplish this, we will give carvedilol to some patients who have diminished heart function and congestive heart failure and see whether symptoms and heart function are better at the end of an 8 month period in those who received carvedilol compared to the other patients who did not receive carvedilol. We will be testing 2 different doses of carvedilol compared to no additional medicine.
NCT00052026 ↗	Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure	Completed	Shaddy, Robert, M.D.	Phase 3	2000-05-01	The purpose of this study is to determine whether a new medicine, called carvedilol, improves symptoms and heart function in children who have congestive heart failure (diminished function of their heart muscle that pumps blood to the body). To accomplish this, we will give carvedilol to some patients who have diminished heart function and congestive heart failure and see whether symptoms and heart function are better at the end of an 8 month period in those who received carvedilol compared to the other patients who did not receive carvedilol. We will be testing 2 different doses of carvedilol compared to no additional medicine.
NCT00000294 ↗	Effects of Carvedilol on Cocaine Use in Humans - 11	Completed	University of Minnesota	Phase 2	1998-09-01	The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00000294 ↗	Effects of Carvedilol on Cocaine Use in Humans - 11	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 2	1998-09-01	The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00000294 ↗	Effects of Carvedilol on Cocaine Use in Humans - 11	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1998-09-01	The purpose of this study is to examine carvedilol effects in response to cocaine.
NCT00004854 ↗	The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure	Completed	National Center for Research Resources (NCRR)	Phase 1	1969-12-31	We would like to see if using Carvedilol in adjunct with Ace inhibitors will increase ejection fraction of the heart under echo. All interpretation of data will be sent to Boston Children's Hospital to be reviewed, which is the primary research center in this study. There are 5 hospitals participating in this study. The population targeted are children with moderate heart failure and must be on Ace inhibitors at the time of enrollment. Our outcome after placing them on Carvedilol is to change their ejection fraction on echo. The patients will be seen every 1-2 weeks, while we will titrate their medication to a maintenance dose. Secondary outcome is to increase quality of life, exercise tolerance and decrease their symptom scores as noted on their questionnaires.

Clinical Trial Conditions for carvedilol

Condition Name

Condition Name for carvedilol
Intervention	Trials
Hypertension	23
Heart Failure	22
Portal Hypertension	13
Healthy	11

Condition MeSH

Condition MeSH for carvedilol
Intervention	Trials
Hypertension	46
Heart Failure	43
Liver Cirrhosis	20
Hypertension, Portal	17

Clinical Trial Locations for carvedilol

Trials by Country

+

−

Trials by Country for carvedilol
Location	Trials
United States	477
Japan	36
China	31
Korea, Republic of	21
Canada	19

Trials by US State

+

−

Trials by US State for carvedilol
Location	Trials
New York	27
Texas	21
California	21
Florida	18
Illinois	16

Clinical Trial Progress for carvedilol

Clinical Trial Phase

Clinical Trial Phase for carvedilol
Clinical Trial Phase	Trials
Phase 4	66
Phase 3	31
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for carvedilol
Clinical Trial Phase	Trials
Completed	96
Unknown status	30
Recruiting	21

Clinical Trial Sponsors for carvedilol

Sponsor Name

Sponsor Name for carvedilol
Sponsor	Trials
GlaxoSmithKline	24
Institute of Liver and Biliary Sciences, India	13
National Heart, Lung, and Blood Institute (NHLBI)	5

Sponsor Type

Sponsor Type for carvedilol
Sponsor	Trials
Other	257
Industry	60
NIH	21

Carvedilol: Clinical Trials, Market Analysis, and Projections

Introduction to Carvedilol

Carvedilol is a non-selective beta-blocker and alpha-1 blocker, widely used in the treatment of heart failure, high blood pressure, and other cardiovascular conditions. Its efficacy and safety have been extensively studied in various clinical trials, and it remains a significant player in the pharmaceutical market.

Clinical Trials Update

Heart Failure in Childhood Cancer Survivors

A recent double-blind, phase 2b clinical trial conducted by City of Hope in cooperation with the Children’s Oncology Group (COG) investigated the use of carvedilol to reduce the risk of heart failure in childhood cancer survivors. This study, involving 182 patients, aimed to mitigate the long-term cardiac adverse effects associated with anthracycline chemotherapy. The results showed that while carvedilol did not significantly reduce the thinning of the heart muscle and enlargement of its chambers, it did improve left ventricular end-systolic wall stress, an earlier biomarker of worsening heart health. The study highlighted that carvedilol was safe and well-tolerated, even at low doses, and suggested its potential as a preventive measure for heart failure in this population[1].

Heart Failure Trials

The US Carvedilol Heart Failure Trials Program, a series of four concurrent, randomized, double-blind, placebo-controlled clinical trials, demonstrated the efficacy of carvedilol in reducing mortality and morbidity in patients with heart failure. The trials, which involved 1094 patients, showed a 65% reduction in mortality risk and a 27% reduction in the risk of hospitalization for cardiovascular causes among patients receiving carvedilol compared to those receiving a placebo. These findings led to the premature termination of the study due to the significant benefits observed with carvedilol therapy[4].

Cost-Effectiveness

An economic evaluation conducted alongside the US Carvedilol Heart Failure Trials Program indicated that carvedilol is not only effective but also cost-saving. The study found that patients receiving carvedilol had lower estimated costs for cardiovascular-related inpatient care compared to those receiving a placebo. The cost per death averted was negative, suggesting that carvedilol both increases survival and decreases healthcare costs[3].

Market Analysis

Global Market Size and Growth

The global carvedilol market is projected to experience significant growth from 2024 to 2031. The market size in 2023 was substantial, and the compound annual growth rate (CAGR) is expected to be robust over the forecast period. This growth is driven by the increasing prevalence of cardiac diseases, such as heart failure and hypertension, which are exacerbated by poor lifestyle choices including high sugar intake, lack of exercise, and consumption of processed foods[2][5].

Regional Market Trends

The Asia Pacific region is expected to account for the largest revenue share by 2037, driven by the rising prevalence of hypertension in low and middle-income countries. In contrast, the North America region is anticipated to maintain a significant market share due to the high prevalence of heart failure and hypertension, coupled with the presence of efficient healthcare infrastructure[5].

Application Segments

The carvedilol market is segmented by application into high blood pressure, congestive heart failure (CHF), ventricular dysfunction, and others. The CHF segment is expected to hold a substantial share in the global market due to the increasing prevalence of CHF, which is often caused by fluid build-up in the heart and high levels of cholesterol[5].

Market Projections

Growth Drivers

The growth of the carvedilol market is driven by several factors:

• Increasing Prevalence of Cardiac Diseases: Heart failure and hypertension are becoming more common globally, driven by lifestyle factors and demographic changes.
• Advancements in Medical R&D: Continuous research and development in medical technologies are expected to enhance the efficacy and accessibility of carvedilol.
• Emergence of New Technologies: New medical technologies and treatment protocols are likely to increase the demand for carvedilol[5].

Challenges

Despite the growth potential, the carvedilol market faces several challenges:

• Side Effects and Adverse Reactions: Although carvedilol is generally well-tolerated, it can cause side effects such as shortness of breath and arthralgia, which may affect patient adherence.
• Regulatory Hurdles: Changes in regulatory environments and healthcare policies can impact the market dynamics and accessibility of carvedilol.
• Competition from Alternative Treatments: The presence of other heart failure treatments, such as angiotensin-converting enzyme inhibitors, may pose competition to carvedilol[1][5].

Key Takeaways

• Clinical Efficacy: Carvedilol has been shown to reduce the risk of heart failure and mortality in various clinical trials, including those involving childhood cancer survivors and patients with chronic heart failure.
• Cost-Effectiveness: The drug is not only effective but also cost-saving, reducing healthcare costs associated with cardiovascular-related inpatient care.
• Market Growth: The global carvedilol market is expected to grow significantly due to the increasing prevalence of cardiac diseases and advancements in medical R&D.
• Regional Trends: The Asia Pacific and North America regions are anticipated to be key markets driven by different factors such as prevalence rates and healthcare infrastructure.

FAQs

What is the primary use of carvedilol in clinical settings?

Carvedilol is primarily used in the treatment of heart failure, high blood pressure, and other cardiovascular conditions.

How does carvedilol benefit childhood cancer survivors?

Carvedilol has been shown to improve left ventricular end-systolic wall stress, an earlier biomarker of worsening heart health, in childhood cancer survivors who received anthracycline chemotherapy.

What are the cost implications of using carvedilol for heart failure?

Studies have indicated that carvedilol is cost-saving, reducing the estimated costs for cardiovascular-related inpatient care and improving survival rates.

Which regions are expected to dominate the carvedilol market?

The Asia Pacific region is expected to account for the largest revenue share by 2037, while the North America region will maintain a significant market share due to high prevalence rates and efficient healthcare infrastructure.

What are the main drivers of the carvedilol market growth?

The growth is driven by the increasing prevalence of cardiac diseases, advancements in medical R&D, and the emergence of new medical technologies.

Sources

1. Targeted Oncology: "Carvedilol May Reduce Heart Failure Risk in Childhood Cancer Survivors"
2. Cognitive Market Research: "Global Carvedilol Market Report 2025 Edition"
3. PubMed: "Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program"
4. PubMed: "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure"
5. Research Nester: "Carvedilol Drug Market Size, Growth Forecasts 2037"